Navigation Links
Cepheid Receives Health Canada Medical Device License for Xpert MRSA(TM) Test and GeneXpert(R) System
Date:1/29/2008

ed genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. See http://www.cepheid.com for more information.

This press release contains forward-looking statements that are not purely historical regarding Cepheid's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to product performance and future market opportunities and market size. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: unforeseen manufacturing problems; regulatory developments and practices regarding testing levels; customer and market acceptance of the product; the failure of products to perform as expected, whether due to manufacturing errors, defects or otherwise; the impact of competitive products and pricing; potentially lengthy sales cycles in some markets; reimbursement rates for the products; and underlying market conditions worldwide. Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K for 2006 and in its most rec
'/>"/>

SOURCE Cepheid
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cepheid to Present at the Piper Jaffray 19th Annual Healthcare Conference
2. Cepheid to Present at William Blair Small-Cap Growth Stock Conference
3. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
4. Cepheid to Present at Thomas Weisel Partners Healthcare Conference
5. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
6. A Magnetic Gift: Sumter Regional Hospital Receives New MRI as Charitable Donation From Siemens
7. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
8. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
9. Neptune Technologies receives GRAS notification in the United States
10. 012 Smile.Communications Receives License to Provide Endpoint Network Services
11. Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... LONDON , March 27, 2015 ... Royal Free Hospital in London , Richmond ... for a global Phase 3 study for an investigational RNAi ... an orphan disease affecting the nerves and heart. ... Record Detail Based at St Georges University ...
(Date:3/27/2015)... Governor Andrew M. Cuomo today announced ... - the world’s largest business idea competition with $5 ... $1 million, six $500,000 awards and four $250,000 awards. ... compete for prizes that will turn ideas with high ... York region. , "Last year's successful 43North competition ...
(Date:3/26/2015)... SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; ... including the appointment of auditors, its annual and special ... "Meeting") was adjourned, as previously disclosed on March 25, ... Toronto time). The date of the ... The Meeting will reconvene at the offices of the ...
(Date:3/26/2015)... and CINCINNATI , March ... (LSE: SHP, NASDAQ: SHPG ) and Cincinnati ... broad research collaboration for rare diseases. The goal of ... therapies to treat rare diseases with high unmet ... with Cincinnati Children,s research expertise. As a nationally ...
Breaking Biology Technology:Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 2Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 3Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 4Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 5SQI Diagnostics Inc. Announces Adjournment of Meeting 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 4Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 5
... - Asian populations with regard to risk associated in the ... osteoporosis or cardiovascular disease, ... in response to nutritional ... WALTHAM, Mass., Feb. 28 Interleukin Genetics,Inc. (Amex: ILI ...
... Transgenomic Inc. (OTC,Bulletin Board: TBIO) announces the following Webcast:, What: ... Conference Call, When: ... http://www.transgenomic.com/events.asp?id=6 , How: ... address above., ...
... ANDS ) today announced that patient dosing has ... oral TLR7 agonist prodrug, in,patients with advanced solid tumors. ... to identify pharmacologically active doses,and preliminary antitumor activity as ... II trials., The Phase I trial is a ...
Cached Biology Technology:Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor 2Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor 3Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor 4Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor 5Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients 2Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients 3Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients 4
(Date:3/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/48tj8z/global_biometrics ... "Global Biometrics Market Forecast and Opportunities, 2020" ... for biometric authentication systems is projected to grow ... The driving forces for this highly ... projects and constant development in technology. In 2014, ...
(Date:3/2/2015)... , March 2, 2015 Synaptics Inc. ... of human interface solutions, today announced a new ... designed to enable rapid and secure transactions and ... for gaming is a turnkey solution providing mouse ... to quickly integrate fingerprint ID solutions into their ...
(Date:3/2/2015)... --  Neurotechnology , a provider of high-precision biometric, robotics ... Development Kit (SDK). The SentiGaze algorithm enables designers ... to track eye movements and generate heatmaps based on ... be used for applications such as analysis of websites ... can also be used to develop interfaces for a ...
Breaking Biology News(10 mins):Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3
... (March 30, 2011)The Society of Interventional Radiology Foundation,s Discovery ... invasive medicine into new areas of discovery, announced a ... provider of medical devices for vascular access and the ... in Marlborough, Mass., has pledged $500,000 and was named ...
... German . , Innovations relating to mobility, energy, ... at the 2011 Hannover Messe from April 4 8. ... a hybrid Porsche racing car, developments in battery research, materials ... European energy supply system, and the Energy Solution Center (EnSoC) ...
... blood be the key to creating cyborg interfaces? Circuitry that ... device, such as a robotic limb or artificial eye might ... components. Writing in the International Journal of Medical ... a "memristor" can be made using human blood. Memristors were ...
Cached Biology News:Fueling interventional radiology growth: SIR Foundation announces Navilyst Medical Pledge 2KIT presents innovations at the 2011 Hannover Messe 2KIT presents innovations at the 2011 Hannover Messe 3KIT presents innovations at the 2011 Hannover Messe 4KIT presents innovations at the 2011 Hannover Messe 5Blood simple circuitry for cyborgs 2
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
... 2000 One-Step FP Standardization Kit is ... low fluorescence polarization values of fluorescein ... Beacon 2000 System. It also allows ... generated by their instrument to the ...
Whole blood is collected from mice (Swiss Webster, 8-10 weeks old,either sex) and processed within 45 minutes of collection. The complement is then filtered and pooled on ice, bottled and stored at -...
Whole blood is collected from healthy guinea pigs of either sex from US source which are free of visible diseases at time of blood collection. Hemolytic titer: CH50 = 435 units...
Biology Products: